Table 3.
Gametocyte prevalence on days 0, 7, 14, 21 and 28 after treatment in patients with adequate parasitological response
| Gametocyte prevalence, %, (n/N) | |||||
| After treatment | |||||
| At enrolment | Day 7 | Day 14 | Day 21 | Day 28 | |
| CQ | 4.7 (2/42) | 12.5 (3/24)* | 4.2 (1/24)* | 6.6 (1/15) | 0 (0/15) |
| AQ | 12.8 (5/39) | 13.1 (5/38)* | 10.5 (4/38)* | 9.6 (3/31) | 0 (0/30) |
| SP | 10.2 (4/39) | 44.4 (16/36) | 33.3 (12/36) | 17.1 (6/35) | 6.1 (2/33) |
| AQ+SP | 2.4 (2/83) | 3.8 (3/80)* | 6.3 (5/80)* | 1.3 (1/75)¶ | 1.3 (1/75) |
| AQ+AS | 3.6 (3/83) | 2.5 (2/80)* | 1.2 (1/79)* | 1.5 (1/64)¶ | 0 (0/64) |
CQ, Chloroquine, AQ, amodiaquine; SP, Sulphadoxine-Pyrimethamine; AS, artesunate; 95% CI, 95% confidence interval.
* On day 7 and day 14, significant difference to SP group (P < 0.05)
¶On day 21, significant difference to SP group (P < 0.05)